NASDAQ:ACOG - Nasdaq - CA02074J5017 - Common Stock - Currency: USD
8.69
-1.16 (-11.78%)
The current stock price of ACOG is 8.69 USD. In the past month the price increased by 71.74%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.77 | 322.91B | ||
AMGN | AMGEN INC | 13.1 | 146.19B | ||
GILD | GILEAD SCIENCES INC | 13.79 | 132.89B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.58B | ||
REGN | REGENERON PHARMACEUTICALS | 13.47 | 64.44B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.59B | ||
ARGX | ARGENX SE - ADR | 99.05 | 35.50B | ||
ONC | BEIGENE LTD-ADR | 5.93 | 25.74B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.82B | ||
NTRA | NATERA INC | N/A | 20.73B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.14B | ||
BIIB | BIOGEN INC | 7.98 | 18.51B |
Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company is headquartered in Vancouver, British Columbia and currently employs 52 full-time employees. The company went IPO on 2021-06-09. The firm is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. The company is in preclinical development for the treatment of ALS.
ALPHA COGNITION INC
c/o 1200 - 750 West Pender Street
Vancouver BRITISH COLUMBIA CA
Employees: 52
Phone: 16045649244
The current stock price of ACOG is 8.69 USD. The price decreased by -11.78% in the last trading session.
The exchange symbol of ALPHA COGNITION INC is ACOG and it is listed on the Nasdaq exchange.
ACOG stock is listed on the Nasdaq exchange.
7 analysts have analysed ACOG and the average price target is 20.4 USD. This implies a price increase of 134.75% is expected in the next year compared to the current price of 8.69. Check the ALPHA COGNITION INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ALPHA COGNITION INC (ACOG) has a market capitalization of 139.21M USD. This makes ACOG a Micro Cap stock.
ALPHA COGNITION INC (ACOG) currently has 52 employees.
ALPHA COGNITION INC (ACOG) has a support level at 7.52. Check the full technical report for a detailed analysis of ACOG support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ACOG does not pay a dividend.
ALPHA COGNITION INC (ACOG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.01).
The outstanding short interest for ALPHA COGNITION INC (ACOG) is 0.25% of its float. Check the ownership tab for more information on the ACOG short interest.
ChartMill assigns a technical rating of 7 / 10 to ACOG.
ChartMill assigns a fundamental rating of 3 / 10 to ACOG. ACOG has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months ACOG reported a non-GAAP Earnings per Share(EPS) of -2.01. The EPS decreased by -40.09% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -28.85% | ||
ROE | -35.3% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to ACOG. The Buy consensus is the average rating of analysts ratings from 7 analysts.